These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 18368304

  • 1. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
    Mathias CJ.
    Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
    [Abstract] [Full Text] [Related]

  • 2. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 3. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 4. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 Aug; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 5. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 6. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
    Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MA.
    J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions.
    Loavenbruck A, Sandroni P.
    Curr Med Res Opin; 2015 Nov; 31(11):2095-104. PubMed ID: 26373628
    [Abstract] [Full Text] [Related]

  • 9. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency.
    Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA.
    Lancet; 1987 Nov 21; 2(8569):1172-5. PubMed ID: 2890807
    [Abstract] [Full Text] [Related]

  • 10. Dopamine B hydroxylase deficiency responsible for severe dysautonomic orthostatic hypotension in an elderly patient.
    Gentric A, Fouilhoux A, Caroff M, Mottier D, Jouquan J.
    J Am Geriatr Soc; 1993 May 21; 41(5):550-1. PubMed ID: 8486891
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O.
    Expert Opin Pharmacother; 2019 Apr 21; 20(6):635-645. PubMed ID: 30730771
    [Abstract] [Full Text] [Related]

  • 13. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983 Apr 21; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 14. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N, Koshikawa S, Akizawa T, Tsubakihara Y, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M.
    Am J Nephrol; 2002 Apr 21; 22(4):338-46. PubMed ID: 12169865
    [Abstract] [Full Text] [Related]

  • 15. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 16. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 12; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 17. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 18. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure.
    Kaufmann H, Oribe E, Yahr MD.
    J Neural Transm Park Dis Dement Sect; 1991 Oct 16; 3(2):143-8. PubMed ID: 1910486
    [Abstract] [Full Text] [Related]

  • 19. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F, Kremens D, Vernino S, Karabin B.
    Clin Auton Res; 2017 Jul 16; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract] [Full Text] [Related]

  • 20. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.